WO2004056313A3 - Prevention and treatment of cardiac arrhythmias - Google Patents

Prevention and treatment of cardiac arrhythmias Download PDF

Info

Publication number
WO2004056313A3
WO2004056313A3 PCT/US2003/040504 US0340504W WO2004056313A3 WO 2004056313 A3 WO2004056313 A3 WO 2004056313A3 US 0340504 W US0340504 W US 0340504W WO 2004056313 A3 WO2004056313 A3 WO 2004056313A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
prevention
cardiac arrhythmias
glucagon
peptide
Prior art date
Application number
PCT/US2003/040504
Other languages
French (fr)
Other versions
WO2004056313A2 (en
Inventor
David R Hathaway
Alain D Baron
Original Assignee
Amylin Pharmaceuticals Inc
David R Hathaway
Alain D Baron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc, David R Hathaway, Alain D Baron filed Critical Amylin Pharmaceuticals Inc
Priority to JP2004562291A priority Critical patent/JP2006514035A/en
Priority to AU2003297356A priority patent/AU2003297356A1/en
Priority to EP03813770A priority patent/EP1610811A4/en
Publication of WO2004056313A2 publication Critical patent/WO2004056313A2/en
Publication of WO2004056313A3 publication Critical patent/WO2004056313A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an intecrin, a glucagon-like peptide-1 (GLP-1), an exendin, or an aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.
PCT/US2003/040504 2002-12-17 2003-12-17 Prevention and treatment of cardiac arrhythmias WO2004056313A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2004562291A JP2006514035A (en) 2002-12-17 2003-12-17 Prevention and treatment of cardiac arrhythmias
AU2003297356A AU2003297356A1 (en) 2002-12-17 2003-12-17 Prevention and treatment of cardiac arrhythmias
EP03813770A EP1610811A4 (en) 2002-12-17 2003-12-17 Prevention and treatment of cardiac arrhythmias

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43450802P 2002-12-17 2002-12-17
US60/434,508 2002-12-17
US43488802P 2002-12-19 2002-12-19
US60/434,888 2002-12-19

Publications (2)

Publication Number Publication Date
WO2004056313A2 WO2004056313A2 (en) 2004-07-08
WO2004056313A3 true WO2004056313A3 (en) 2004-11-25

Family

ID=32685317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/040504 WO2004056313A2 (en) 2002-12-17 2003-12-17 Prevention and treatment of cardiac arrhythmias

Country Status (4)

Country Link
EP (1) EP1610811A4 (en)
JP (1) JP2006514035A (en)
AU (1) AU2003297356A1 (en)
WO (1) WO2004056313A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108939052A (en) * 2018-09-04 2018-12-07 江苏省中医药研究院 Purposes of the Exenatide in the drug of preparation prevention or treatment atrial fibrillation

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2005077094A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US8404637B2 (en) 2005-02-11 2013-03-26 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
US8946149B2 (en) 2005-04-11 2015-02-03 Amylin Pharmaceuticals, Llc Use of exendin and analogs thereof to delay or prevent cardiac remodeling
EP2330124B1 (en) * 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
CN101296942A (en) * 2005-08-11 2008-10-29 安米林药品公司 Hybrid polypeptides with selectable properties
WO2007139941A2 (en) * 2006-05-26 2007-12-06 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
RU2413528C2 (en) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Exenatide and dalargin drug for treating diabetes, adminisration and therapy
JP2009019027A (en) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd Insulin secretion peptide derivative in which amino acid of amino terminal is varied
JP2010539064A (en) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Thyrotropin-releasing hormone for therapeutic applications
WO2010068735A1 (en) 2008-12-10 2010-06-17 Glaxosmithkline Llc. Pharmaceutical compositions
JP2013525491A (en) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
EP2771025A1 (en) * 2011-10-28 2014-09-03 Pharis Biotec GmbH A polypeptide for the protection against heart ischemia-reperfusion injury
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
CA2895156A1 (en) 2012-12-21 2014-06-26 Sanofi Dual glp1/gip or trigonal glp1/gip/glucagon agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (en) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Peptide for medical treatment of pancreatic diabetes of 2nd type and its complications
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
AR105284A1 (en) 2015-07-10 2017-09-20 Sanofi Sa DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
EP3474820B1 (en) 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1 compositions and uses thereof
CN110551203B (en) * 2019-09-25 2023-02-10 成都奥达生物科技有限公司 Exenatide analogue
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As Glp-1 compositions and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US20020107206A1 (en) * 2000-05-19 2002-08-08 Coolidge Thomas R. Treatment of acute coronary syndrome with GLP-1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
ES2291017T3 (en) * 1998-02-13 2008-02-16 Amylin Pharmaceuticals, Inc. INOTROPIC AND DIURETIC EFFECTS OF EXENDINE AND GLP-1.
CA2380423A1 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
JP4480329B2 (en) * 2000-10-20 2010-06-16 アミリン・ファーマシューティカルズ，インコーポレイテッド Treatment of hibernating myocardium and diabetic cardiomyopathy with GLP-1 peptide
WO2002085406A1 (en) * 2001-04-24 2002-10-31 Restoragen, Inc. Methods and compositions for treating conditions associated with insulin resistance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US20020107206A1 (en) * 2000-05-19 2002-08-08 Coolidge Thomas R. Treatment of acute coronary syndrome with GLP-1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NIKOLAIDIS ET AL.: "GLP-1 improves myocardial performance in conscious dogs with pacing induced heart failure", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 37, no. 2, February 2001 (2001-02-01), pages 218A, XP001053523 *
See also references of EP1610811A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108939052A (en) * 2018-09-04 2018-12-07 江苏省中医药研究院 Purposes of the Exenatide in the drug of preparation prevention or treatment atrial fibrillation
CN108939052B (en) * 2018-09-04 2021-03-16 江苏省中医药研究院 Application of exenatide in preparation of medicine for preventing or treating atrial fibrillation

Also Published As

Publication number Publication date
JP2006514035A (en) 2006-04-27
AU2003297356A8 (en) 2004-07-14
EP1610811A2 (en) 2006-01-04
EP1610811A4 (en) 2008-03-26
WO2004056313A2 (en) 2004-07-08
AU2003297356A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
WO2004056313A3 (en) Prevention and treatment of cardiac arrhythmias
WO2000066138A3 (en) Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
WO2001098331A3 (en) Glucagon-like peptide-1 analogs
WO2004056317A3 (en) Compositions for the treatment and prevention of nephropathy
WO2006024275A3 (en) Glp-1 and exendin related invention
WO1999043705A8 (en) N-terminally truncated glp-1 derivatives
NO20010982L (en) Method of administering insulinotropic peptides
WO2004069158A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
WO2004100875A3 (en) Benzimidazoles, compositions containing such compounds and methods of use
AU2002322403A1 (en) Glucagon-like peptide-1 analogs
WO2001068112A3 (en) Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
WO2006119260A3 (en) Combination of dipeptidyl peptidase-iv inhibitor and a cannabinoid cb1 receptor antagonist for the treatment of diabetes and obesity
DK1412357T3 (en) Beta-aminotetrahydroimidazo (1,2-a) pyrazines and tetrahydrotriazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1585959A4 (en) Extended glucagon-like peptide-1 analogs
DK1523325T3 (en) Methods and compositions for the treatment of polycystic ovarian syndrome
EP1773330A4 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
EP1756074A4 (en) 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007078815A3 (en) Certain chemical entities, compositions, and methods
WO2006086727A3 (en) Treating diabetes with glucagon-like peptide-1 secretagogues
WO2000034331A3 (en) Analogues of glp-1
WO2007089336A3 (en) Certain chemical entities, compositions and methods
WO2004032852A3 (en) Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
WO2003000181A3 (en) Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2001036365A3 (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
EP2085086A3 (en) Method for treating congestive heart failure or diabetic nephropathy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004562291

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003813770

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003813770

Country of ref document: EP